• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS INSPIRIS RESILIA AORTIC VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS INSPIRIS RESILIA AORTIC VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Model Number 11500A
Device Problems Fluid/Blood Leak (1250); Gradient Increase (1270); Patient-Device Incompatibility (2682)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 05/16/2023
Event Type  Injury  
Manufacturer Narrative
Additional narratives: surgical/percutaneous intervention is indicated or performed, or harm occurred due to the device, or there is a device malfunction that could cause or contribute to a serious injury.This event is considered a serious injury.The device was not returned for evaluation, as it remains implanted.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.
 
Event Description
It was reported that a 23mm aortic valve developed regurgitation and prosthesis patient mismatch after an approximate implant duration of 3 months.The patient currently is asymptomatic and is being evaluated for a valve-in-valve procedure.Per index procedure records, after implantation of the 23mm inspiris valve, post bypass echo showed lv function with a normally functioning aortic valve with no evidence of any paravalvular leak.On 3-month post-op visit the tte showed increased gradient due to prosthesis patient mismatch.
 
Manufacturer Narrative
H10: additional manufacturer narrative: updated sections: b4, b6, g3, g6, h2.
 
Manufacturer Narrative
H10: additional manufacturer narrative: updated sections: b4, d4, g3, g6, h2, h4, h6 (type of investigation, investigation findings, and investigation conclusions).Complaint is confirmed through provided medical records.There is no evidence to suggest an edwards manufacturing defect.Capa/scar is not required.Root cause analysis: per imaging evaluation, the submitted echocardiographic images are remarkable for.Documentation of high transvalvular velocity and gradients on both sets of tte images, and documentation of normal bioprosthesis leaflet appearance and motion on the latter tte and no suggestion of anatomic structural valve deterioration or ar on either.Both submitted tte studies document high transvalvular velocity and gradients in the absence of bioprosthesis dysfunction.There is a small interval increase in velocity and gradients between the (b)(6) 2022 tte and the (b)(6) 2022 tte accompanied by an associated increase in svi; suggesting that incrementally higher flow probably accounts for the observed small changes in hemodynamics.Additional factors that could be contributing to high velocity and gradients in the absence of prosthesis dysfunction include intracavitary lv systolic flow acceleration and pressure recovery.A dhr review was performed and no related manufacturing nonconformances were identified.Per drm (b)(4), rev d, patient prosthesis mismatch (ppm) is present when the effective orifice area of the inserted prosthetic valve is too small in relation to body size.Its main hemodynamic consequence is to generate higher than expected gradients through a normally functioning prosthetic valve.Evaluation of provided tee images was able to confirm the customer report of elevated gradients but was unable to confirm the report of aortic regurgitation.Based on the information provided, a definitive root cause was unable to be determined.All pertinent information available to edwards lifesciences has been submitted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS INSPIRIS RESILIA AORTIC VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer Contact
saurav singh
one edwards way
mle fl2- office m2013
irvine, CA 92614
9492506615
MDR Report Key17100989
MDR Text Key316943428
Report Number2015691-2023-13564
Device Sequence Number1
Product Code LWR
UDI-Device Identifier00690103194982
UDI-Public(01)00690103194982(17)260223(11)220224219222680
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P150048
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 07/17/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/09/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number11500A
Device Catalogue Number11500A23
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received07/06/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/24/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Life Threatening; Required Intervention; Hospitalization;
Patient Age57 YR
Patient SexMale
-
-